BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target
BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ: CAI ) with a Buy and maintains $32 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.